TVThasarat Sutabutr Vajaranant

Thasarat Sutabutr Vajaranant

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thasarat Sutabutr Vajaranant has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Mary N. Haan

    Department of Epidemiology and Biostatistics (M.N.H.), University of California at San Francisco, San Francisco, California, USA

    6 shared publications
  • Jacob T Wilensky

    Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL, USA

    5 shared publications
  • Louis R. Pasquale

    Affiliation Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America

    5 shared publications
  • Abhishek Sethi

    Illinois Eye and Ear Infirmary, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, USA

    4 shared publications
  • Jacob T. Wilensky

    Illinois Eye and Ear Infirmary, Department of Ophthalmology and Visual Sciences, University of Illinois, Chicago, Ill

    4 shared publications
  • Pauline M. Maki

    Department of Psychiatry (P.M.M.), University of Illinois at Chicago, Chicago, Illinois, USA

    4 shared publications

Latest Publications

  • Open Access

    Comparative insights into the role of sex hormones in glaucoma among women and men

    by Sharon H. Zhao, Christine K. Kim, Tala Al-Khaled, Margaret Ann Chervinko, Anne Wishna, Rukhsana G. Mirza, Thasarat Sutabutr Vajaranant


  • Melatonin as an adjuvant: reshaping glaucoma treatment strategies

    by Moonis Ali, Sirimon Reutrakul, Thasarat Sutabutr Vajaranant


  • Pregnancy outcomes in the medical management of glaucoma: An international multicenter descriptive survey

    by Aaron R Kaufman, Leyla Ali Al-Djasim, Angeline C Rivkin, Muneera Al-Futais, Ganesh Venkataraman, Menaka Vimalanathan, Abhipsa Sahu, Navjot Singh Ahluwalia, Rakesh Shakya, Thasarat Sutabutr Vajaranant, et al.

    Purpose: To determine if glaucoma medications are associated with pregnancy and/or postnatal complications. Methods: Multicenter descriptive survey. Subjects were female patients 18–45 years who were previously pregnant with a diagnosis of glaucoma or ocular hypertension prior to pregnancy. Chart review queried diagnosis, glaucoma severity, and race. Survey questions were asked for each pregnancy and queried pregnancy age, medications used, and pregnancy outcomes/complications. Results: 114 pregnancies of 56 patients (mean 2.0 pregnancies per patient) were included. Three pregnancies with therapeutic abortion were excluded from further analysis. Mean age during pregnancy was 29.1 ± 5.7 years. Of the 111 pregnancies, 20 (18.0%) used no medications and 91 (82.0%) used at least one medication. Medications were topical carbonic anhydrase inhibitors (n = 45), beta-blockers (n = 55), alpha-agonists (n = 56), and prostaglandin analogues (n = 28). Outcomes were: preterm contractions/labour (6.3%), miscarriage (4.5%), stillbirth (4.5%), induction of labour (11.9%), emergency/unplanned caesarean delivery (13.9%), neonatal intensive care unit (NICU) stay (15.8%), congenital anomalies (8.1%), and low birth weight (10.9%). Fisher exact test assessed outcome associations with individual agents, use of any agent, and different number of agents. Alpha-agonist use was associated with NICU stay: 25.5% rate ( p = 0.012) in alpha-agonist use. Most of the alpha-agonist use NICU stays occurred in pregnancies with third trimester use. All other associations were not statistically significant. Conclusions: The data from this survey suggest an overall favourable safety profile for topical glaucoma medications in pregnancy, but further investigation is needed. Caution should be employed regarding third trimester alpha-agonist use owing to association with NICU stay.


  • Open Access

    Which OCT parameters can best predict visual field progression in glaucoma?

    by Abhishek Sethi, Homa Rashidisabet, Joelle A. Hallak, Thasarat Sutabutr Vajaranant


  • Topical netarsudil for treatment of glaucoma with elevated episcleral venous pressure: A pilot investigation in sturge-weber syndrome

    by Aaron R Kaufman, Abdelrahman M Elhusseiny, Deepak P Edward, Thasarat Sutabutr Vajaranant, Ahmad A Aref, Javaneh Abbasian

    Purpose: Topical netarsudil 0.02% may reduce intraocular pressure (IOP) by decreasing episcleral venous pressure (EVP), which carries theoretical utility for glaucoma associated with elevated EVP. A role for netarsudil in patients with elevated EVP is evaluated in a pilot investigation using a cohort of individuals with Sturge-Weber syndrome (SWS). Methods: Retrospective study of patients with SWS and glaucoma who were treated with netarsudil. Five patients (six eyes) were identified. Data collected included demographics, visual acuity, IOP, glaucoma medical and surgical treatments, and adverse effects of netarsudil. Results: Mean age was 13.6 ± 8.5 years. EVP elevation was presumed based on clinical stigmata and/or historical features. Mean number of baseline glaucoma medications was 3.3 ± 1.2. There was a significant reduction in the IOP at netarsudil initiation (mean 26.2 ± 4.5 mmHg) to 1 month of netarsudil therapy (mean 20.2 ± 3.8 mmHg, p = 0.0283 ) and latest IOP on netarsudil (mean 17.6 ± 1.4 mmHg, p = 0.0034). Mean duration of netarsudil therapy was 18.7 ± 11.8 months. Three patients required additional glaucoma procedures; one patient required an additional glaucoma medication. Three eyes (50%) developed conjunctival hyperemia. One patient discontinued netarsudil at 29 months, to reduce drop burden. Conclusions: Netarsudil can effectively reduce IOP in patients with SWS, even when used as a fourth or fifth glaucoma medication. A possible role for netarsudil in the management of patients with elevated EVP is suggested pending further future investigations.


  • An Association Between Large Optic Cupping and Total and Regional Brain Volume: The Women's Health Initiative

    by Catherine Wang, Sasha Kravets, Abhishek Sethi, Mark A. Espeland, Louis R. Pasquale, Stephen R. Rapp, Barbara E. Klein, Stacy M. Meuer, Mary N. Haan, Pauline M. Maki, et al.


  • Effect of Low-Fat Dietary Modification on Incident Open-Angle Glaucoma

    by Rajvi Mehta, Roberta M. Ray, Lisa Marie Tussing-Humphreys, Louis R. Pasquale, Pauline Maki, Mary N. Haan, Rebecca Jackson, Thasarat Sutabutr Vajaranant


  • Open Access

    Association between cognitive function and large optic nerve cupping, accounting for cup-disc-ratio genetic risk score

    by Sasha Kravets, Rawan Allozi Rupnow, Abhishek Sethi, Mark A. Espeland, Louis R. Pasquale, Stephen R. Rapp, Barbara E. Klein, Stacy M. Meuer, Mary N. Haan, Pauline M. Maki, et al.

    Purpose: To investigate if accounting for a cup-to-disc ratio (CDR) genetic risk score (GRS) modified the association between large CDR and cognitive function among women. Design: This was a retrospective study using data from the Women’s Health Initiative. Methods: Patients with glaucoma or ocular hypertension were excluded. Large CDR was defined as ≥ 0.6 in either eye. Cognitive function was measured by the Modified Mini-Mental State Examination (3MSE). We used the combined effects from 13 single nucleotide polymorphisms (SNPs) to formulate the GRS for CDR. We used logistic regression to investigate associations between weighted GRS and large CDR, then a linear regression to assess the association between weighted GRS and 3MSE scores, and between weighted GRS, CDR, and 3MSE scores, adjusted for demographic and clinical characteristics. Results: Final analyses included 1,196 White women with mean age of 69.60 ± 3.62 years and 7.27% with large CDR. Mean GRS in women with and without large CDR was 1.51 ± 0.31 vs. 1.41 ± 0.36, respectively (p = 0.004). The odds of large CDR for a one unit increase in GRS was 2.30 (95% CI: (1.22, 4.36), p = 0.011). Adding the CDR GRS in the model with CDR and 3MSE, women with large CDR still had statistically significantly lower 3MSE scores than those without large CDR, yielding a predicted mean difference in 3MSE scores of 0.84 (p = 0.007). Conclusions: Independent of the CDR GRS, women with large CDR had a lower cognitive function.


  • Clinical Dilemma—Topical Prostaglandin Use in Glaucoma During Pregnancy

    by Thasarat Sutabutr Vajaranant

    Glaucoma management during pregnancy presents a unique clinical challenge because of potential risks to the fetus and the lack of large-scale safety and efficacy data on glaucoma treatment in this population.1 A 2007 survey conducted in the United Kingdom indicates uncertainty among ophthalmologists regarding glaucoma management during pregnancy.2 Approximately one-third of the responding ophthalmologists reported having experiences treating patients with glaucoma during pregnancy. When the ophthalmologists were asked about their treatment choices for patients with evidence of glaucoma progression during pregnancy, 31% stated that they were unsure about which treatment to use, 40% reported they would continue the prepregnancy treatment, and 17% noted they would continue observing the patient without prescribing treatment. In terms of medication choices, 45% chose topical β-blockers while 33% used topical prostaglandins. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.


  • Blunt Anterior Segment Trauma

    by Rebecca Deutsch Sarran, Bruce M. Zagelbaum, Thasarat Sutabutr Vajaranant